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A B S T R A C T   
Hemoglobin-based oxygen carriers have long been pursued to meet clinical needs by using native hemoglobin 
(Hb) from human or animal blood, or recombinantly produced Hb, but the development has been impeded by 
safety and toxicity issues. Herewith we report the successful production of human fetal hemoglobin (HbF) in 
Nicotiana benthamiana through Agrobacterium tumefaciens-mediated transient expression. HbF is a hetero-
tetrameric protein composed of two identical α- and two identical γ-subunits, held together by hydrophobic 
interactions, hydrogen bonds, and salt bridges. In our study, the α- and γ-subunits of HbF were fused in order to 
stabilize the α-subunits and facilitate balanced expression of α- and γ-subunits in N. benthamiana. Efficient 
extraction and purification methods enabled production of the recombinantly fused endotoxin-free HbF (rfHbF) 
in high quantity and quality. The transiently expressed rfHbF protein was identified by SDS-PAGE, Western blot 
and liquid chromatography-tandem mass spectrometry analyses. The purified rfHbF possessed structural and 
functional properties similar to native HbF, which were confirmed by biophysical, biochemical, and in vivo 
animal studies. The results demonstrate a high potential of plant expression systems in producing Hb products for 
use as blood substitutes.   
1. Introduction 
Human hemoglobin (Hb) in the red blood cells (RBCs) of vertebrates 
has an essential role in oxygen transport. With an aging population, 
increased number of surgical interventions and a reduced amount of 
blood donors available, meeting the demand for donated blood has 
become more challenging [1]. Meanwhile, patient refusal of donated 
blood for religious, ethical or medical reasons further affects the use [2]. 
These factors have driven efforts to develop “Hemoglobin-based oxygen 
carriers” (HBOCs) as a potential resource for emergency clinical treat-
ments of acute anemia, resulting from severe blood loss. HBOCs have 
potential advantages over human blood, such as universal compatibility, 
better availability, lack of blood-borne pathogen transmission risks, 
improved rheological properties and enhanced shelf life [3]. Besides 
blood transfusion, several other fields of oxygen therapeutics, including 
oxygenation of organs to be transplanted, have been proposed. 
Hb is a heterotetrameric heme-protein consisting of four subunits 
held together by non-covalent interactions. Each subunit contains a 
heme group, a porphyrin with an iron ion bound in the center, which is 
capable of binding and releasing oxygen [4]. In humans, a number of 
different Hb forms have been described, two major types are adult Hb 
(HbA) and fetal Hb (HbF). HbA is composed of two α- and two β-subunits 
(α2β2), while HbF consists of two α- and two γ-subunits (α2γ2). HbF is 
predominantly produced during the last seven months of fetal devel-
opment in the uterus, accounting for 50-95% of an infant's total Hb, but 
is gradually replaced by HbA after birth and constitutes less than 1% of 
total Hb by the age of two years. Transfusion of HbF appears to be ad-
vantageous under certain conditions, such as sickle cell disease and 
β-thalassemia where the function of HbA is impaired [5,6]. Since HbF 
has higher oxygen (O2) affinity than HbA [7,8], and in combination with 
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an increased protein stability [9], it may suggest that HbF is better suited 
as an HBOC compared to HbA [10]. Furthermore, severely sick preterm 
infants and extremely low body weight premature infants require blood 
transfusion to replace blood loss during intensive care and surgery 
[11–13]. However, transfusion of adult donor blood (containing HbA) to 
neonates has demonstrated an increased risk of a devastating intestinal 
disease, necrotizing enterocolitis and immune sensitization [14]. Alto-
gether, this makes HbF may be an interesting future alternative to cur-
rent RBC transfusions for anemic preterm infants and possibly also in 
other clinical applications. 
Development of HBOCs has been hampered by safety issues and lack 
of efficient scalable production systems [2]. Extensive efforts have been 
made to develop HBOCs either using Hbs purified from animal or human 
RBC, or by designing recombinantly produced Hbs with improved O2 
binding kinetics, reduced nitric oxide (NO) binding, reduced renal 
toxicity, and other desirable properties; but unfortunately, the progress 
has been slow [2,7]. Furthermore, the efforts to develop HBOCs through 
recombinant expression techniques in microbial systems have encoun-
tered some additional challenges [15]. This includes inclusion body 
formation [16], instability of the alpha subunit [17], insufficient ca-
pacity to supply heme, and several strategies have been proposed to 
overcome these obstacles [15]. Heme is a non-covalently bound pros-
thetic group of Hb, and heme-binding to globin subunits is crucial to 
yield functionally active Hb [18]. Hb lacking heme (apo-Hb) is unstable 
and degrades quickly [19]. Addition of heme, or heme precursor, 
δ-aminolevulinic acid to the medium is thus needed for producing 
functional Hb in the bacterial system [19,20], this is however cost 
ineffective. Furthermore, microbial production constitutes a risk of 
introducing endotoxins to the HBOC-treated patients [21,22]. The 
presence of endotoxins in the bloodstream may be toxic and can lead to 
systemic inflammation, septic shock, organ failure and death [23]. 
Compared with microbial production systems, the production of Hbs 
in plants offers some significant advantages [24]. Plants are capable of 
synthesizing heme [25]. This capacity would greatly facilitate produc-
tion of recombinant Hb. Also, plant expression system has eukaryotic 
post-translational modification, such as cleavage of N-terminal methi-
onine, which is essential for proteins' functional activity and stability 
[26]. Moreover, production of therapeutic proteins in plants is regarded 
as safe due to the absence of human pathogens and no risk of introducing 
endotoxins. There are in principle two approaches to express proteins in 
plants, namely stable and transient gene expression. Stable expression 
approach is time consuming as it requires production of transgenic 
plants first, and the expression level is often low [27,28]. Recently, 
agrospray-based transient expression using plant viral vectors has been 
developed for efficient production of heterologous proteins [29–31]. 
This approach has been demonstrated to produce high-level expression 
of pharmaceutical proteins in Nicotiana benthamiana, which has been 
considered as a robust, low cost, sustainable and scalable protein factory 
[32,33] and several of the plant-produced proteins are currently un-
dergoing clinical trials [34]. 
One major challenge of heterologous production of the hetero-
tetrameric HbF is that free Hb α-subunits are unstable in monomeric 
form, and only stable in dimeric or tetrameric forms of Hb [35]. Fusion 
of α- and γ-subunits of HbF (fHbF) has been shown to stabilize the 
α-subunits that are dependent on a cofactor during and after folding 
without need of expressing additional chaperones. Furthermore, this 
ensures an equal level of expression of the α- and γ-subunits [36]. In this 
study, we fused the α- and γ-subunits to produce a recombinant fused 
HbF (rfHbF) and transiently expressed it in N. benthamiana using a viral 
vector delivered by Agrobacterium. The purified protein was shown to be 
stable and displayed functional properties similar to native HbF, thus 
enabling further development towards a possible use as an HBOC. 
2. Materials and methods 
2.1. Agrobacterium strain 
Agrobacterium tumefaciens strain GV3101 was used to deliver the 
viral vectors into the plant cells in this study. 
2.2. Plant material 
N. benthamiana plants were grown in a controlled climate growth 
chamber in biotron at SLU, Lomma, at day and night temperatures of 
25 ◦C and 20 ◦C, respectively, with 60% relative humidity, 250 μmol m-2 
s-1 photosynthetic photon flux density and 18 h photoperiod throughout 
the study. 
2.3. Construction of viral vectors 
Human α (HBA1) and γ (HBG2) Hb genes according to the sequences 
(accession numbers: P69905 and P69892) in the Uniprot database were 
codon optimized for N. benthamiana and synthesized by Thermo Fisher 
Scientific. The AvrII and XhoI restriction sites were added to facilitate 
cloning. A Kozak sequence (GCCACC) [37] was added in the 5′-UTR of 
the α-gene and a 12-amino acid linker (3 Gly-Gly-Ser repeats) was added 
to fuse the α and γ sequences as described previously [36], with the α in 
the 5′ end position as well as two stop codons at the end of the fused 
gene. The recombinant and fused gene is denoted as rfHbF hereafter. The 
synthesized rfHbF gene was cloned into a tobacco mosaic virus (TMV) 
based viral vector, pJL-TRBO [38], resulting in the vector, named pJL- 
TRBO-rfHbF, as shown in Supplementary Fig. S1. After sequence 
confirmation, the vector was transformed into A. tumefaciens, strain 
GV3101. Similarly, the pJL3:P19 vector harboring the P19 gene of to-
mato bushy stunt virus (TBSV) for suppressing posttranscriptional gene 
silencing was also transformed into this strain for co-application later 
on. 
2.4. Agrospray 
Agrobacterium suspensions of pJL-TRBO-rfHbF and pJL3:P19 were 
prepared separately, as described previously [38]. For agrospray, the 
two suspensions were diluted to OD of 0.025 at 600 nm first, and then 
mixed at a 2:1 ratio in favor of pJL-TRBO-rfHbF. Agrobacterium sus-
pension of the empty vector pJL-TRBO was also prepared in the same 
way as stated above to serve as control. The diluted suspensions, sup-
plemented by surfactant, Silwet L-77 (Vac-In-Stuff; Lehle Seeds, Round 
Rock, TX, USA) at 0.1% (v/v) were sprayed onto mature leaves of 4− 6 
weeks old N. benthamiana using a hand-held spray. 
2.5. Sampling of leaves and protein extraction 
Leaf samples from non-sprayed and sprayed plants with the pJL- 
TRBO-rfHbF and pJL-TRBO vectors were collected at day 9 after the 
spray and kept at -80 ◦C for further use. Before protein extraction, the 
frozen leaves were homogenized to fine powder in liquid nitrogen. 
Proteins were extracted using 2 v/w extraction buffer consisting of 10 
mM sodium phosphate buffer (pH 6.0), supplemented with 10 mM so-
dium metabisulfite and 0.05% plant protease inhibitor cocktail (P9599, 
Sigma-Aldrich) at 4 ◦C. To increase protein production level, a second 
spray was done after harvesting initially sprayed leaves, altogether ca. 
30− 40 g of leaves (fresh weight) could be harvested per plant. 
2.6. Protein purification 
The rfHbF protein purification steps included heating in the presence 
of carbon monoxide (CO), addition of polyvinylpolypyrrolidone (PVPP), 
dialysis and chromatography purification. For heat treatment, the total 
soluble protein extract, saturated with CO with addition of 2% (w/v) 
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PVPP, was kept at 60 ◦C for 5 min, followed by centrifugation at 12000 
rpm for 10 min at 4 ◦C. Thereafter, the supernatant was decanted, 
saturated with CO and filtered through a 0.45 μm filter. The filtered 
protein extracts were dialyzed in 5 mM sodium phosphate buffer (pH 
6.0) at 4 ◦C, overnight, using dialysis flasks (Slide-A-Lyzer, 10 K MWCO, 
Thermo Scientific). The dialyzed protein samples were filtered through a 
0.45 μm filter, saturated with CO and purified using two chromato-
graphic steps as described previously [39]. The first purification step 
was cation exchange chromatography (CM Sepharose, GE Healthcare), 
where the column was equilibrated with 10 mM sodium phosphate 
buffer (pH 6.0) before loading the sample, followed by elution with 70 
mM sodium phosphate buffer, pH 7.2. For the second chromatography 
step, the samples were buffer exchanged to 20 mM Tris-HCl buffer, pH 
8.3 and purified using an anion exchange chromatography column (Q- 
HP, 5 mL, GE Healthcare), pre-equilibrated with the same buffer. The 
protein samples were eluted with a gradient of 50 mM sodium phosphate 
buffer containing 100 mM sodium chloride (NaCl), pH 7.2. The purified 
rfHbF protein was finally concentrated by centrifugation with Vivaspin 
columns (30 K MWCO, Sartorius) and snap-frozen in liquid nitrogen in 
the CO-liganded state, and stored at -80 ◦C until use. Native HbF was 
purified from whole blood, freshly drawn from umbilical cord blood, as 
previously described [40]. 
2.7. Absorbance spectra, ligand binding and oxygen equilibrium curve 
analysis 
Absorbance spectra of rfHbF protein samples in the presence or 
absence of different ligands were determined using a Cary 60 UV–Vis 
spectrophotometer (Agilent technologies) in the range of 250–700 nm at 
room temperature in quartz cuvettes with a 1 cm path length. A carboxy- 
rfHbF sample was generated by bubbling the sample with CO and then 
measuring under CO in a sealed cuvette. Oxy-rfHbF was obtained by 
applying a continuous stream of oxygen to carboxy-rfHbF solution, 
under strong light. Met-rfHbF was produced by incubation of oxy-rfHbF 
with an excess of potassium ferricyanide. This solution was then passed 
through a gel filtration column Sephadex G-25 (5 × 0.5 cm, GE 
Healthcare) to remove excess ferricyanide. Deoxy-rfHbF was obtained 
by addition of a few grains of sodium dithionite to the oxidized sample. 
2.8. Estimation of rfHbF quantity 
The rfHbF protein was quantified using the carboxy-Hb extinction 
coefficient at 419 nm [41], measured by a Cary 60 UV–Vis spectro-
photometer. All assays were carried out with at least three independent 
biological replicates. 
2.9. Analyses of the rfHbF-protein by sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot 
The purity and specificity of rfHbF were determined by SDS-PAGE 
and Western blot analyses, respectively under reducing conditions. 
Prior to SDS-PAGE, the protein extracts sampled after different steps of 
purification as well as native HbF control were heated at 95 ◦C for 20 
min with loading dye, Bolt sample buffer and Bolt reducing agent 
(Thermo Fisher Scientific). The protein samples were run on Bolt 4-12% 
Bis/Tris gels (Thermo Fisher Scientific), and stained with Gelcode™ 
blue safe protein stain or SimplyBlue™ Safe Stain (Thermo Fisher Sci-
entific) according to the manufacturers' instructions, followed by de- 
staining with Milli-Q water. Western blot was performed according to 
the manufacturer's instructions (Thermo Fisher Scientific) using an 
iBlot™ 2 polyvinylidene difluoride (PVDF) Mini Stack and the iBlot™ 2 
System, using the default program (Thermo Fisher Scientific). Rabbit 
polyclonal anti-HbF primary antibody (targeting gamma (γ)-subunit) 
and goat anti-rabbit IgG secondary antibody conjugated to horseradish 
peroxidase (HRP) (Thermo Fisher Scientific) diluted 1:2000 in blocking 
buffer were used for Western blot analysis. The results were visualized 
using Novex® ECL is a Chemiluminescent Substrate Reagent Kit (Invi-
trogen) and a ChemiDoc™ MP Imaging System (Bio-Rad). 
2.10. Protein identification and molecular weight determination 
For protein identification, the purified rfHbF was retrieved by cut-
ting out the band from the SDS-PAGE gel, digested with trypsin, and 
analyzed by liquid chromatography (LC) (Dionex, Breda, The 
Netherlands), coupled with quadrupole mass spectrometry (MS/MS). 
Mass spectrometric data obtained from quadrupole time of flight (Q- 
TOF) Ultima instrument (Waters, Sollentuna, Sweden) were recorded 
with charge state of 2 and 3 (SCIBLU Proteomics Resource Centre, Lund 
University, Lund). For rfHbF protein identification, tandem MS spectra 
of the tryptic peptides were analyzed using the Mascot Daemon (version 
2.3; Matrix Science Ltd., London, UK) database with settings for carba-
midomethylation of cysteines fixed and variable oxidation of methio-
nine residues. For molecular weight determination, the protein sample 
was first further purified by reversed phase HPLC (Agilent 1200 system) 
using a short C8 column before being analyzed on a Q-TOF mass spec-
trometer (Bruker Maxis Impact system). The molecular weight of the 
protein was determined using a deconvolution algorithm (MaxEnt 
software, Micromass, Manchester, UK) that calculates the weight of the 
intact non-protonated peptides (Alphalyse A/S, Odense, Denmark). For 
further identity confirmation and methionine cleavage, the purified 
rfHbF was transferred from SDS-PAGE to a PVDF membrane by elec-
troblotting. The band corresponding to the rfHbF protein was excised 
and the sequence of the five N-terminal amino acids of the protein was 
determined by Edman degradation using a Procise Protein Sequencing 
System (Applied Biosystems) (Alphalyse A/S, Odense, Denmark). 
2.11. Size exclusion chromatography (SEC) 
Molecular weight of the rfHbF was determined using SEC. Sample 
(50 μM, heme equivalent) in 50 mM sodium phosphate buffer, pH 7.4 
plus 150 mM NaCl, was loaded onto Superdex® Hiload 16/60, HR col-
umn (GE Healthcare) that was pre-equilibrated with the same buffer. 
The column was connected to an ÄKTA Explorer (GE Healthcare, Swe-
den), and elution of the sample was monitored at 419 and 280 nm. The 
molecular weight of the rfHbF was calculated using a calibration curve 
of the known molecular weight markers. 
2.12. Circular dichroism (CD) spectroscopy 
CD measurements of rfHbF and native HbF were carried out with a 
Chirascan spectropolarimeter (Applied Photophysics, Leatherhead, UK). 
Far-UV (190–260 nm) CD measurements of oxy-rfHbF (concentration of 
5.0 μM heme) were performed in 1 mm quartz cuvettes in 100 mM so-
dium phosphate buffer, pH 7.4 at 4 ◦C. Data was collected using a 
bandwidth of 1 nm, a step size of 1 nm and a time per point of 0.5 s. The 
instrument was flushed with nitrogen at a flow rate of 5 L/min. Spectra 
were accumulated five times and the values were corrected for buffer 
contributions. Data was analyzed using Spectra Manager II software 
(Jasco, Easton, MD, USA). The samples were stored at 4 ± 1 ◦C prior to 
far-UV or CD analysis. Thermal stability experiments were monitored 
from 20 to 90 ◦C using CD spectroscopy with the samples incubated at 
each temperature for 5 min before the CD spectra were collected. 
Melting temperature values were estimated using sigmoidal fits of 
thermal denaturation curves at 222nm performed using the OriginLab 
(version 2018b) Boltzmann function. 
2.13. Dynamic light scattering (DLS) 
The purified protein was also analyzed by DLS in a Zetasizer APS 
instrument (Malvern Panalytical). The rfHbF sample was diluted to 0.3 
mg/mL in 10 mM phosphate buffered saline (PBS), pH 7.4 and measured 
at 20 ◦C with six replicates. 
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2.14. Oxygen binding assay 
Oxygen equilibrium curves of rfHbF and native HbF (concentration 
of 94 μM heme equivalent) were recorded on an oxygenation- 
dissociation analyser (BLOODOX-2018 Analyser, Softron Biotech-
nology, Beijing, China) in 4 mL of BLOODOX-Solution buffer, pH 7.4 
(130 mM NaCl (Chinese Medicine Group Chemical Agent, Beijing, 
China), 30 mM TES (Sigma Aldrich, St Louis, MO, USA) and 5 mM KCl 
(Chinese Medicine Group Chemical Agent, Beijing, China), at 37 ◦C, as 
described previously [42]. P50, a partial pressure of O2 at which the 
heme-binding sites in the rfHbF samples are 50% saturated with O2 was 
calculated using the formula as mentioned previously [42]. Hill coeffi-
cient (n), a measure of co-operativity in O2 binding was calculated from 
the Hill plot (log Y/(1-Y) vs. log P), where Y was fractional saturation of 
rfHbF with oxygen and P was the oxygen pressure in mmHg [43]. 
2.15. Autoxidation kinetics 
In order to estimate the autoxidation rate of rfHbF, CO was first 
removed by bubbling with air under a strong light, which was followed 
by two G25 PD10 buffer change steps into air equilibrated buffer (100 
mM sodium phosphate buffer, 1 mM EDTA, pH 7.4). The oxy- and deoxy- 
rfHbF spectra (after sodium dithionite addition) were measured to 
confirm CO removal and the sample was diluted to ~5 μM concentration 
(heme). Catalase (C40, Sigma-Aldrich) and superoxide dismutase 
(S9395-15KU, Sigma-Aldrich) were added at ~3 mmol/mol concentra-
tion. The samples, in triplicate, were incubated in sealed cuvettes in a 
water bath at 37 ◦C, and measurements were taken every 2 h for the first 
10 h in a Multiskan GO spectrophotometer (Thermo Fisher Scientific), 
followed by measurements at approximately, 20–24 h, 51–55 h and 
70–74 h the following days, with a similar 2 h interval. Prior to each 
measurement, the cuvettes were gently inverted twice. The change in 
absorbance at 576 nm was used to estimate the autoxidation rate, after 
subtracting from the detected values of the average absorbance at 
690–700 nm for each timepoint, to compensate for some apparent 
variation in overall background. The values were fitted to a single 
exponential equation with an offset, using excel solver and the 
nonlinear-GRG solving method. 
2.16. Endotoxin assay 
The endotoxin content of rfHbF was assessed by a Limulus Amebo-
cyte Lysate (LAL)-kinetic chromogenic assay with method D described in 
the Section 2.6.14 of the European Pharmacopoeia with the addition of 
β-glucan blocker to prevent false positives due to β-glucan-like mole-
cules. All measurements were performed by Lonza (Verviers, Belgium). 
The assay was run along with an endotoxin standard, diluted serially at 
five standard concentrations (50 EU/mL–0.005 EU/mL), to generate a 
standard curve to determine the concentration of endotoxin in rfHbF. 
2.17. Animal studies 
The animal protocols were approved by the Swedish animal ethics 
committee in Malmö/Lund, Sweden, prior to the study. The purified 
rfHbF was injected intravenously into female BALB/c mice (Janvier, Le 
Genest-Saint-Isle, France) in a maximum volume of 0.2 mL to a total 
amount of 5 mg per mouse. The mice were then euthanized at various 
time points to collect blood and urine samples. Blood and urine samples 
were collected at ~5 min, 2, 6 and 24 h after the injection. Weight and 
body temperature were recorded at 24 h after the rfHbF injection. Sur-
face body temperature was recorded using a non-invasive Mini IR 
thermometer (Extech 42510A or Hioki FT3701-20) directed to the lower 
abdominal region of the mice. The mice were euthanized and cardiac 
puncture used to collect blood in tubes containing sodium citrate. 
Citrated plasma was generated by centrifugation and frozen at -80 ◦C 
until further use. 
rfHbF concentrations in plasma and urine samples were measured 
using a sandwich ELISA assay. Microtiter plates (MaxiSorp, Nunc) were 
coated with a rabbit polyclonal anti-human HbF antibody (“Bonita”, 
Agrisera AB, Vännäs, Sweden; prepared after immunization with puri-
fied human γ-subunit and specific anti-HbF IgG antibodies were affinity 
purified as described [40]) at 4 μg/mL in PBS and incubated overnight at 
4 ◦C. The plate was washed 4× with wash buffer (PBS-T, Medicago AB, 
Uppsala, Sweden) and then the wells were blocked with the blocking 
buffer (1% BSA in PBS-T) overnight at 4 ◦C. The wells were washed 
twice with wash buffer followed by addition of either 100 μL of rfHbF 
standard or diluted plasma or urine samples. The plasma samples and 
standard rfHbF series were diluted 1:20–1:4000 in blocking buffer 
containing CD1 murine plasma (Seralab, West Sussex, UK) to equalize 
the final plasma concentration. The urine samples were diluted 1:50 or 
1:250 in blocking buffer. Upon incubation for 2 h at room temperature, 
the plate was washed 4× with wash buffer. To detect bound rfHbF, 100 
μL of sheep anti-human HbF-HRP conjugate (Bethyl Labs, Montgomery, 
TX, USA), diluted 1:2000 in blocking buffer was added to the plate and 
incubated for 2 h at room temperature with gentle shaking, protected 
from light. Upon washing 4× with the wash buffer, the plate was 
developed with 100 μL TMB single solution (Invitrogen) for about 10 
min and absorbance measured at 650 nm. The plasma half-life was 
calculated using Microsoft Excel software with the Solver add in (Excel 
2013). Unpaired t-tests were used to verify significant differences be-
tween samples from different time-points using GraphPad Prism 9.0.0 
(GraphPad Software, La Jolla, CA, USA). 
SDS-PAGE and Western blot analyses of the mouse plasma and urine 
samples were carried out under reducing conditions as described above. 
Presence of rfHbF in plasma and urine at different time-points was tested 
by diluting citrated plasma samples 20× in PBS and the urine samples 
10× in PBS before loading 4 μL of sample per well. 
Urea nitrogen was measured in mouse plasma using the Quanti-
Chrom Urea Assay kit (Cat#DIUR-100, BioAssay Systems, Hayward, CA, 
USA). Mouse albumin in the urine samples was measured using a mouse 
albumin ELISA kit (Cat#ab108792, Abcam, Cambridge, UK). Moreover, 
the urine samples were assayed for creatinine using the QuantiChrom 
Creatinine Assay kit (Cat#DICT-500, BioAssay Systems, Hayward, CA, 
USA). Since a small sample size per group was used, nonparametric 
Kruskal-Wallis analysis of variance for repeated measures (ANOVA) 
with Dunn's multiple comparison post hoc test were chosen to analyze 
the albumin to creatinine ratio (ACR) and blood urea nitrogen (BUN) 
data. The data was statistically analyzed using GraphPad Prism 9.0.0 
(GraphPad Software, La Jolla, CA, USA) and differences were considered 
statistically significant if P < 0.05. 
The presence of rfHbF protein in urine was investigated by reading 
the absorbance spectra using a UV–Vis spectrophotometer (Multiskan 
GO Microplate Spectrophotometer, Thermo Scientific). Spectra of 
carboxy-rfHbF and deoxy-rfHbF were obtained as described previously. 
3. Results 
3.1. Successful expression of the human HbF protein in plant expression 
system 
In this study, we have expressed rfHbF in N. benthamiana leaves 
through transient expression with the viral pJL-TRBO-rfHbF vector 
delivered by Agrobacterium using the scalable agrospray method. Anal-
ysis of protein extracts with SDS-PAGE (Fig. 1a) showed the expression 
of the rfHbF protein in the leaves sprayed with Agrobacterium harboring 
the target gene, while as expected, no rfHbF bands were detected in the 
extract of leaves without agrospray or those sprayed with the empty 
vector. Efficient extraction and purification of target proteins from plant 
cells are essential for ensuring high recovery of the functional protein. In 
this study, we achieved high yield and purity of the functional protein 
through extraction at acidic pH (pH 6), heat treatment, dialysis and two 
steps of ion-exchange chromatography. The thermo-tolerant nature of 
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the carboxy-form of the rfHbF protein helped to preserve the rfHbF 
structure during heating while removing impurities (Fig. 1b). After 
purification with cation and anion-exchange chromatography, about 
70% of the rfHbF could be recovered with a purity of approximately 
95% as estimated by SDS-PAGE (Fig. 1c) and a maximum yield of rfHbF 
of about 80–100 mg/kg of leaves (fresh weight). 
3.2. Protein size verification and size exclusion chromatography (SEC) 
The purified rfHbF protein showed a band with the expected mo-
lecular weight (~32 kDa of fused α- and γ-subunits of rfHbF) when 
analyzed by SDS-PAGE (Fig. 1c), and was further confirmed by Western 
blot analysis (Fig. 1d). No band detected at ~16 kDa (Fig. 1c and d) for 
rfHbF suggests that the linker that fused the α- and γ-subunits was not 
disrupted during the protein extraction and purification and was intact 
in solution. In contrast, the native HbF (Lane 4 in Fig. 1c) migrated as 
monomeric Hb subunits (~16 kDa), as previously reported under 
denaturing conditions [44]. The purified rfHbF samples were subjected 
to SEC in order to probe the homogeneity of the samples and molecular 
weight of the protein. The peak in the SEC chromatogram corresponds to 
an apparent molecular weight of 29.3 kDa (Fig. 1e) according to the 
calibration curve (Fig. 1f). 
3.3. Mass spectrometric analysis and N-terminal sequencing of rfHbF 
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) was 
used to confirm the identity of the produced rfHbF protein, covering 
43.3% of the amino acid sequence (Fig. 2a). Moreover, ESI-MS was used 
to measure the molecular weight, which was determined to be 
31,906.45 Da (Fig. 2b), closely matching the theoretical molecular 
weight of rfHbF: 31,906.34 Da, without methionine. N-terminal 
sequencing confirmed that the rfHbF protein lacked the methionine 
residue, suggesting efficient removal of the N-terminal methionine in 
N. benthamiana (Supplementary Table S1). 
3.4. Biochemical and biophysical characterization 
The co-ordination of heme within the Hb subunits is crucial for 
stabilizing the rfHbF structure and for its O2 transport capability, how-
ever, the oxidation of the ferrous (Fe2+) heme to ferric (Fe3+) heme 
renders the protein inactive, and may lead to dissociation of heme from 
the Hb subunits [45]. The detected ultraviolet-visible (UV–Vis) spectra 
indicated that the rfHbF protein was correctly folded with correct Fe2+, 
heme cofactor incorporation (Fig. 2c). As shown in the Fig. 2c, the 
spectra of rfHbF have a single predominant peak in the Soret region, 
(419 nm for carboxy-rfHbF, 415 nm for oxy-rfHbF, 430 nm for deoxy- 
rfHbF and 405 nm for met-rfHbF). The longer wavelengths “Q-bands” 
are also seen in the Fig. 2c at 539 and 569 nm for carboxy-rfHbF, 541 
and 576 nm for oxy-rfHbF, as well as the characteristic peaks at 630 nm 
for the Fe3+, met-rfHbF. The absorbance spectra of rfHbF were very 
similar to the native HbF as previously reported [10]. The absorbance 
spectra of rfHbF in the presence and absence of ligands indicate that the 
rfHbF protein was functional, capable of binding its ligands. 
Far-UV circular dichroism (CD) is a powerful analytical tool to 
determine protein conformation and stability in solution. CD spectra can 
be used to gain information on the relative proportions of secondary 
structure elements, α-helical, β-sheet and random coil. To evaluate the 
secondary structure of the rfHbF protein, we determined its far-UV CD 
spectra at 190–260 nm (Fig. 2d). Our results showed that the absorbance 
in the far-UV region was essentially identical for rfHbF and native HbF, 
indicating that the HbF subunit fusion in rfHbF and the extraction and 
purification processes did not result in disruptions of the secondary 
structure (Fig. 2d). A qualitative interpretation of the spectra with 
double minima around 207 and 222 nm implies that the dominant 
secondary structure elements in the rfHbF protein are α-helixes, a typical 
structure of globin proteins contributed by n → π* transition for the 
peptide bond of the α-helix [46]. This is in good agreement with the 
native HbF [47]. Taken together, these results imply that the subunits of 
the rfHbF protein produced in N. benthamiana are folded identically to 
the native HbF. To assess the tetrameric state of functional rfHbF, we 
measured hydrodynamic diameter of rfHbF using DLS and the result 
showed an average hydrodynamic diameter of 5.3 ± 0.15 nm (standard 
deviation, n = 6), similar to that of native tetrameric Hb (~5.5 nm) [48]. 
To determine temperature stability, we also analyzed the CD spectra of 
oxy-rfHbF and native oxy-HbF at temperatures ranging from 20 ◦C to 
90 ◦C with 5 ◦C intervals (Fig. 2e and f). The melting points (Tm) of both 
native HbF and rfHbF were estimated to be above 60 ◦C, indicating high 
thermal stability of both proteins. 
3.5. Oxygen equilibrium analysis 
We measured the oxygen binding affinity of both rfHbF and native 
HbF proteins using an oxygenation-dissociation analyser and the results 
are shown as oxygen equilibrium curves (Fig. 2g). The partial pressure of 
oxygen at half saturation of the proteins (P50) and Hill coefficient (n) 
were calculated. The detected P50 value (8.94 mmHg) of rfHbF detected 
was lower than that of native HbF (12.11 mmHg) indicating that rfHbF 
binds oxygen more tightly, i.e., higher oxygen affinity (Fig. 2g). The 
calculated Hill coefficients for rfHbF and native HbF were 1.61 and 2.37, 
respectively, indicating a lower co-operativity of rfHbF compared to the 
native HbF. 
3.6. Autoxidation of rfHbF 
The spontaneous oxidation (autoxidation) of Fe2+ heme iron to Fe3+
in rfHbF was measured in the presence of the antioxidant enzymes, su-
peroxide dismutase (superoxide ion scavenger) and catalase (peroxide 
scavenger). The detected autoxidation rate of 0.02 ± 0.0014 h-1 was 
comparable to, and slightly lower than, that previously reported for 
E. coli produced rHbF in the presence of catalase (0.03 ± 0.0059 h-1) 
[49]. 
3.7. Endotoxin analysis 
As we used the gram-negative Agrobacterium to deliver the viral 
vector carrying the target gene into the plant cells, we examined the 
Fig. 1. Transient expression, purification, detection and characterization of the rfHbF protein produced in the leaves of Nicotiana benthamiana. (a) SDS-PAGE gel 
showing rfHbF protein from the leaves at day 9 after agrospray. Lane 1, Non-sprayed control; Lane 2, agrospray with empty vector; Lane 3. agrospray with pJL-TRBO- 
fHbF vector. Image is representative of three independent experiments. Extracts containing 10 μg protein were loaded for each sample. Lane 4, the protein extract 
non-saturated with carbon monoxide (CO) during heat treatment (60 ◦C for 10 min); Lane 5, the protein extract saturated with CO during heat treatment (60 ◦C for 
10 min). (b) UV–Vis absorbance spectra of the rfHbF protein extract saturated with CO (orange line) and without CO (purple line) during heating at 60 ◦C for 10 min 
with an enlarged insert at 450–600 nm. Data represent the average of three biological replicates. (c) The final purified rfHbF protein of 5 μg on SDS-PAGE gel. (d) The 
final purified rfHbF protein (5 μg) from Western blot analysis. For (a) and (c) M, SeeBlueTM Plus2 Pre- Stained Protein Standard molecular weight marker with 
weights (kDa). For (d) M1, MagicMarkTM XP Western Protein Standard molecular weight marker with weights (kDa). For (c) and (d), orange arrows indicate the 
rfHbF bands. Lane 1, sample after heat treatment. Lane 2, sample after cation exchange chromatography. Lane 3, sample after anion exchange chromatography. Lane 
4, native HbF. (e) Size exclusion chromatogram showing purified rfHbF. Elution volumes of the calibration standards ferritin (440 kDa), aldolase (158 kDa), con-
albumin (75 kDa), carbonic anhydrase (29 kDa) and ribonuclease (13.7 kDa), are indicated. (f) A calibration curve used for determining an apparent molecular 
weight of rfHbF (closed triangle). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.) 
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endotoxin level along with the purified rfHbF using the Limulus 
Amebocyte Lysate (LAL) assay. The result showed that the endotoxin 
level was less than 0.031 units (EU)/mg rfHbF. 
3.8. Pharmacokinetic studies of rfHbF in mouse 
The pharmacokinetic behavior of rfHbF was evaluated in vivo by 
injecting the purified protein in BALB/c female mice. Urine and plasma 
samples were collected at ~5 min, 2, 6 and 24 h after the injection. The 
rfHbF protein could be detected in plasma up to 6 h after the injection, 
but not at 24 h (Fig. 3a). The calculated half-life of rfHbF in plasma was 
~36 min, similar to the previously reported half-life of native HbF [50]. 
In urine, rfHbF was detected at 2 and 6 h, but not at 5 min or 24 h 
(Fig. 3b). Albumin to creatinine ratio (ACR) in urine was estimated, to 
serve as an indicator of kidney functionality. Though ACR was increased 
after rfHbF injection, it was not significant at any of the time points 
Fig. 2. Biophysical and biochemical analyses of purified rfHbF protein extracted from the leaves of N. benthamiana. (a) Amino acid sequence and peptide coverage 
map of rfHbF. Highlighted sequences correspond to peptides detected by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis covering 43.3% of 
the amino acid sequence. (b) Molecular weight (Da) of the purified rfHbF protein was determined using ESI-MS. The molecular weight of rfHbF was 31,906.45 Da, 
very close to the expected theoretical weight of 31,906.34 Da, indicating correct expression and processing, i.e., the N-terminal methionine was cleaved off. (c) 
Representative absorbance spectra of rfHbF protein after binding to different ligands, 250–700 nm with an enlarged insert at 450–650 nm. The spectra of rfHbF have 
a single predominant peak in the Soret peak region at 419 nm for carboxy-rfHbF, 415 nm for oxy-rfHbF, 430 nm for deoxy-rfHbF and 405 nm for metrfHbF, “Q- 
bands” at 539 and 569 nm for carboxy-rfHbF, 541 and 576 nm for oxy-rfHbF, as well as the characteristic peaks at 630 nm for the met-rfHbF. (d) The secondary 
structure of rfHbF protein. Overlay of the far-UV (190–260 nm) circular dichroism (CD) spectra of native HbF and plant produced rfHbF. (e) Thermal stability 
analysis of the oxy-rfHbF by circular dichroism (CD) spectroscopy. (f) Thermal stability analysis of the oxy-native HbF by CD spectroscopy. Boltzmann sigmoidal fit 
(Red) of CD thermal denaturation curve at 222 nm depicting a melting temperature of 60.3 ◦C for oxy-rfHbF (Black) and 60.9 ◦C for oxy-native HbF (Black). The 
unfolding transitions were monitored after thermal equilibration for 5 min with 5 ◦C intervals from 20 to 90 ◦C. (g) Oxygen binding curves of rfHbF and native HbF 
proteins. The partial pressure of oxygen (pO2) at half saturation of HbF (50% sO2) was found to be 8.94 mmHg for rfHbF and 12.11 mmHg for native HbF in 130 mM 
NaCl, 30 mM TES and 5 mM KCl, pH 7.4 at 37 ◦C. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of 
this article.) 
Fig. 3. Pharmacokinetic studies in mice injected with purified rfHbF protein. (a) rfHbF in plasma. (b) rfHbF in urine. For a and b, the analyses were carried out using 
samples collected at different time-points after the protein injection. The levels of rfHbF were measured using an ELISA assay as described in materials and methods, 
and are presented as means ± standard deviation (SD). The red dashed line indicates the lower limit of detection in the assay. The black dotted line indicates a 
hypothetical continued decrease of the rfHbF concentration. (c) Urine albumin to creatinine ratio (ACR) in the mice injected with the protein at 5 min, 2, 6 and 24 h 
(means ± SD, n = 2–5) (C = Control, non-injected) after the injection. Data was analyzed with nonparametric Kruskal-Wallis test followed by Dunn's multiple 
parameter post-hoc test using the GraphPad Prism program (GraphPad Software, La Jolla, CA, USA). (d) Blood urea nitrogen (BUN) levels at 5 min, 2, 6 and 24 h (C 
= Control, non-injected) in plasma samples of the mice injected with rfHbF (means ± SD, n = 2–5). Asterisks above the bar represent statistically significant dif-
ferences between the treatments at p ≤ 0.01, analyzed using the same program as stated in (c). (For interpretation of the references to colour in this figure legend, the 
reader is referred to the web version of this article.) 
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(Fig. 3c). A significant increase in blood urea nitrogen (BUN) level in the 
plasma samples was detected at 6 h after the injection, while no sig-
nificant difference compared to the non-injected control animals were 
observed at 5 min, 2 and 24 h (Fig. 3d). The weight and body temper-
ature of the rfHbF-exposed mice showed no significant differences 
compared to the non-exposed mice (Supplementary Table S2). 
SDS-PAGE and Western blot analyses showed the presence of rfHbF 
in plasma at 5 min as well as in the urine sample collected at 2 h, 
whereas rfHbF was almost non-detectable in plasma at 2 h after the 
injection (Fig. 4a and b). Since the α- and γ-subunits were fused, the 
purified rfHbF protein with the molecular weight of ~32 kDa is 
considered as monomer in this study, equivalent to dimer of native HbF. 
The Western blot analysis showed the presence of monomeric rfHbF, 
along with a small quantity of tetrameric and degraded product of rfHbF 
(Fig. 4b, lane 3) in the urine. The absorbance spectra of rfHbF in the 
urine samples collected at 2 h after the injection showed a main peak at 
410 nm in the Soret region and peaks at 538 nm (β-band) and 576 nm 
(α-band), suggesting that the protein has preserved its native structure in 
the urine and is present as a mixture of oxy-rfHbF and met-rfHbF 
(Fig. 4c). 
4. Discussion 
The attempts of developing HBOCs through heterologous expression 
techniques in microbial systems have only been partially successful in 
the past. One challenge is that Hb production needs to have heme 
incorporated into the Hb subunits for proper folding and function. 
However, most microbial production systems produce insufficient heme 
themselves, which increases the production cost and complicates the 
production process. Consequently, the expression of Hbs is often 
accompanied by production of the apo-Hb [51]. Moreover, the bacterial 
expression systems can cause formation of inclusion bodies, which leads 
to low production efficiency [52]. For the synthesis of a multisubunit 
protein, an equimolar ratio between the subunit molecules is necessary. 
Our initial attempts to produce HbF by co-expression of chimeric α- and 
γ-subunits in two independent expression vectors with the respective 
clones of recombinant Agrobacterium in N. benthamiana was not suc-
cessful, probably due to unbalanced expression of the α- and γ -subunits. 
To address the challenges posed by heterologous expression of Hbs in 
microbial systems, and expressing complex heterodimeric protein in 
N. benthamiana, we have evaluated a plant-based expression system for 
expressing rfHbF using a viral vector harboring the target gene with 
Fig. 4. Detection of rfHbF in plasma and urine of the treated mice. The plasma and urine samples were diluted with phosphate buffered saline (PBS) buffer by 20×
and 10×, respectively and analyzed by SDS-PAGE and Western blot. Samples of 4 μl were loaded in each well. (a) SDS-PAGE (b) Western blot. M, SeeBlueTM Plus2 
Pre-Stained Protein Standard molecular weight marker with weights (kDa). M1, MagicMarkTM XP Western Protein Standard molecular weight marker with molecular 
weights (kDa). Lanes 1 and 2, the plasma samples collected at 5 min and 2 h after the rfHbF injection, respectively; Lane 3: urine sample collected 2 h after the rfHbF 
injection. (c) UV–Vis absorbance spectra of mouse urine collected at 2 h after the rfHbF injection. The insert shows the region at 500–625 nm. The spectra of the 
collected urine sample appeared to show a mixture of met- and oxy-form of rfHbF. 
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fused α- and γ-subunits, joined by a small peptide linker, a design 
intended to help stabilize the α-subunit and ensure balanced expression 
of both subunits. This is, to our knowledge, a novel strategy to produce 
functional human Hbs in plants. 
Heterologous expression of a heterodimeric metallic protein like Hb, 
requiring specific cofactors, heme, for correct folding adds additional 
challenges. To produce fully functional rfHbF, proper heme incorpora-
tion is essential. It has been shown that the E. coli expression system 
often results in sub-optimal heme incorporation into Hbs due to the 
limited amount of free heme available in the culture medium, leading to 
rapid denaturation of the Hb [19]. Our results show that heme seemed to 
be successfully incorporated into rfHbF, evidenced by correct spectra 
and limited loss by heat treatment (Hb subunits without heme, apo-
globin, often aggregate and degrade quickly at high temperature) [19]. 
Since rfHbF did not carry any peptide sequence for targeting to a specific 
compartment, the detection of rfHbF in the agrosprayed leaves in this 
study indicates that the heme insertion into Hb subunits most likely took 
place in the cytosol. Studies on subcellular localization of plant Hbs also 
indicate that they are expressed in the cytosol [53]. As shown in this 
study (Figs. 1b and 2c), heme incorporation into Hbs in the plant 
expression system has occurred without need for overexpressing en-
zymes responsible for heme biosynthesis, possibly indicating the abun-
dant nature of heme in plant cells. However, more studies are required to 
confirm whether heme availability is a limiting factor for further 
increased expression levels of Hbs in plants. In plants, heme is synthe-
sized in chloroplasts and mitochondria and delivered to the cytosol 
[25,54]. It has previously been suggested that the heme-biosynthetic 
pathway in plants is highly conserved and that the levels of heme are 
strictly controlled by the retrograde signaling in the chloroplasts to 
regulate the expression of nuclear genes. Based on the results of this 
study, we suggest that the overexpression of Hb protein in the cytosol 
could possibly hijack the heme biosynthetic pathway by interfering with 
the signal, and thus stimulate overproduction of heme iron in the 
chloroplast/mitochondria in order to meet the increased cellular 
demand. 
The majority of the host cell proteins (HCPs), including most of the 
abundant ribulose-1,5-bisphosphate carboxylase oxygenase (RuBisCO) 
protein [55], could be removed by heat treatment, a convenient and 
low-cost method [56]. Moreover, many of these host cell proteins 
including RuBisCO have low solubility at pH 6 [57,58] and their quick 
removal might have been beneficial for rfHbF stability during the 
extraction and purification processes. Our results have shown that the 
heat treatment with extraction buffer at low pH prior to further purifi-
cation was effective at removing most unwanted compounds, while 
maintaining the majority of the rfHbF protein. The soluble holo-rfHbF 
(Hb protein with bound heme) can be quickly separated from the apo- 
rfHbF by heating, as apo-rfHbF is denatured at high temperature [19]. 
This has also added the benefit of avoiding interference from active 
plant enzymes in the later dialysis and column chromatography steps. 
Contamination with endotoxins could be a concern since endotoxins 
are known to be pyrogenic and cause shock reactions in mammals [23]. 
Our data shows that the expression and purification techniques 
employed to produce rfHbF is highly effective to minimize and/or 
remove potentially contaminating endotoxins derived from the Agro-
bacterium inoculums. Agrospray with diluted agrobacterial suspensions 
(OD600-0.025), protein purification with heating [59], cation- and 
anion-exchange chromatography, and ultrafiltration were found to 
reduce the weakly bound low and high molecular weight endotoxins 
below threshold levels (5 EU per kg of body weight an hour) set by all 
pharmacopoeias for intravenous applications [60]. The detected endo-
toxin level (0.031 units (EU)/mg of purified rfHbF) in this studysuggests 
that the high doses of rfHbF expected to be administered in a possible 
pharmaceutical use as an HBOC would be acceptable. 
The P50 value of rfHbF (8.94 mmHg) was slightly lower than that of 
the non-fused rHbF produced in E. coli (9.6 mmHg) [39] and native HbF 
(12.11 mmHg), suggesting a high oxygen affinity of plant produced 
rfHbF compared with E. coli produced non-fused rHbF and native HbF. 
The high oxygen affinity of plant produced rfHbF could possibly help 
prevent premature oxygen off-loading in arterioles preventing vaso-
constriction and allowing for downstream O2 delivery in capillaries 
[61,62] and may confer a neuroprotective effect in the vulnerable region 
of the hippocampus [63]. The Hill coefficient (1.61) for rfHbF indicates 
higher cooperativity of the plant produced rfHbF compared to that of the 
E. coli produced non-fused rHbF (1.20) [39] and a lower cooperativity 
than native HbF (2.37). The higher affinity and lower cooperativity of 
rfHbF than native HbF were probably associated with the fusion of α- 
and γ-subunits in the rfHbF. The higher oxygen affinity property of 
rfHbF probably would help to deliver oxygen to the most hypoxic tissues 
[7]. Interestingly, the oxygen therapeutic, Hemospan (MP4) that had 
gone through early clinical trials exhibited high oxygen affinity (P50 ~ 5 
mmHg) with minimal cooperative oxygen binding (1.2) [61]. 
Cell free oxygen bound Fe2+ Hb is spontaneously oxidized to non- 
functional Fe3+ met-Hb and the subsequent reactions lead to heme 
damage and eventually heme degradation [64]. Autoxidation of Fe2+ Hb 
is a serious concern for the use of Hb as oxygen therapeutics, as it 
compromises the function and safety [65]. In this study, it was shown 
that rfHbF had a slightly decreased rate of autoxidation, as compared to 
non-fused rHbF produced in E. coli [49], suggesting that fusion of α- and 
γ-subunits does not affect the stability of this protein towards autoxi-
dation. Given the somewhat elevated oxygen affinity observed for 
rfHbF, a lower autoxidation rate would be in line with the inverse cor-
relation between Hb oxygen affinity and autoxidation rate noted pre-
viously [43,64], although other factors such as degree of Hb tetramer 
formation may also play a role in determining autoxidation rate [66]. 
The observed half-life (~36 min) of the rfHbF was in agreement with 
previous studies where it was reported as 0.1 ± 0.1 h in mice infused 
with native HbF [50]. The detection of rfHbF in the urine sample 2 h 
after the injection indicates that the rfHbF was rapidly cleared from the 
blood circulation and filtrated through the glomerulus into the urine. 
Indeed, an increased level in urinary ACR detected after the injection, 
supports a transient effect of rfHbF on kidney glomerular permeability. 
This effect was, however, not significant. This is in agreement with 
previous study in rats where HbF-injection resulted in a transiently 
increased glomerular permeability [67]. Furthermore, a significant in-
crease in plasma BUN at 6 h after injection suggests that rfHbF may have 
a broad effect on kidney glomerular filtration. However, plasma BUN 
displayed tendencies to return to baseline, i.e., similar levels as the 
control animals, indicating that the effect of rfHbF is temporary. Alto-
gether, the in vivo data indicates that a fusion of the α- and γ-subunits 
does not seem to be a viable strategy to prolong circulation time. The 
main reason for fusing the subunits was however to facilitate the protein 
production rather than extend circulatory half-life. Further improve-
ments of the pharmacokinetic properties are therefore warranted, 
employing strategies such as further encapsulation or desolvated 
nanoparticle [4,68] using the described rfHbF as an HBOC platform. 
In conclusion, we were able to successfully produce rfHbF in sig-
nificant quantity in a plant expression system by transient expression 
using scalable agrospray technique. The rfHbF protein could be effi-
ciently purified to the high degree needed for functional studies in vitro 
and in vivo. The purified rfHbF protein was shown to possess structural 
and functional properties similar to native HbF. The present study has 
shown the feasibility of producing large amounts of rfHbF in plants, 
perhaps a first step towards using the plant expression system for pro-
duction of Hbs for HBOC research and future medical applications. 
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than medicines, Annu Rev Anal Chem (Palo Alto, Calif) 9 (2016) 271–294. 
[25] R. Tanaka, A. Tanaka, Tetrapyrrole biosynthesis in higher plants, Annu. Rev. Plant 
Biol. 58 (2007) 321–346. 
[26] G. Friso, K.J. van Wijk, Posttranslational protein modifications in plant 
metabolism, Plant Physiol. 169 (2015) 1469–1487. 
[27] M. Sabalza, P. Christou, T. Capell, Recombinant plant-derived pharmaceutical 
proteins: current technical and economic bottlenecks, Biotechnol. Lett. 36 (2014) 
2367–2379. 
[28] W. Dieryck, J. Poyart, M. Marden, V. Gruber, P. Bournat, S. Baudino, B. Merot, 
Human haemoglobin from transgenic tobacco, Nature 386 (1997) 29–30. 
[29] S. Schulz, A. Stephan, S. Hahn, L. Bortesi, F. Jarczowski, U. Bettmann, A.- 
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